Journal
ANTIOXIDANTS & REDOX SIGNALING
Volume 32, Issue 16, Pages 1188-1236Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/ars.2019.7763
Keywords
glucose; ketogenesis; lipogenesis; mitochondrial nutrients; biomarkers
Funding
- National Basic Research Program of China [973 program] [2015CB856302, 2015CB553602]
- National Natural Science Foundation of China [81741110, 31770917, 31570777, 31870848, 81802787]
- China Postdoctoral Science Foundation [2018M643673]
- State Key Laboratory of Space Medicine Fundamentals and Application, Chinese Astronaut Research and Training Center [SMFA15K01]
Ask authors/readers for more resources
Significance: Epidemiological studies indicate that metabolic disorders are associated with an increased risk for Alzheimer's disease (AD). Metabolic remodeling occurs in the central nervous system (CNS) and periphery, even in the early stages of AD. Mitochondrial dysfunction has been widely accepted as a molecular mechanism underlying metabolic disorders. Therefore, focusing on early metabolic changes, especially from the perspective of mitochondria, could be of interest for early AD diagnosis and intervention. Recent Advances: We and others have identified that the levels of several metabolites are fluctuated in the periphery before their accumulation in the CNS, which plays an important role in the pathogenesis of AD. Mitochondrial remodeling is likely one of the earliest signs of AD, linking nutritional imbalance to cognitive deficits. Notably, by improving mitochondrial function, mitochondrial nutrients efficiently rescue cellular metabolic dysfunction in the CNS and periphery in individuals with AD. Critical Issues: Peripheral metabolic disorders should be intensively explored and evaluated for the early diagnosis of AD. The circulating metabolites derived from mitochondrial remodeling represent novel potential diagnostic biomarkers for AD that are more readily detected than CNS-oriented biomarkers. Moreover, mitochondrial nutrients provide a promising approach to preventing and delaying AD progression. Future Directions: Abnormal mitochondrial metabolism in the CNS and periphery is involved in AD pathogenesis. More clinical studies provide evidence for the suitability and reliability of circulating metabolites and cytokines for the early diagnosis of AD. Targeting mitochondria to rewire cellular metabolism is a promising approach to preventing AD and ameliorating AD-related metabolic disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available